- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study2021 | Faculty of Medicine in Hradec Králové
- Long-term safety of ocrelizumab in the treatment of multiple sclerosis2020 | Faculty of Medicine in Pilsen
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | First Faculty of Medicine, Second Faculty of Medicine
- Elevated D-dimer as an immediate response to alemtuzumab treatment2021 | Second Faculty of Medicine
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study2023 | First Faculty of Medicine
- Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study2021 | Publication without faculty affiliation
- Alemtuzumab2014 | First Faculty of Medicine
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use2015 | First Faculty of Medicine
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study2014 | First Faculty of Medicine
- Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma2023 | First Faculty of Medicine
- Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency2014 | First Faculty of Medicine
- Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study2018 | First Faculty of Medicine
- A Multi-Center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency2022 | Faculty of Medicine in Hradec Králové
- Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma2022 | First Faculty of Medicine
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma2017 | Publication without faculty affiliation
- Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study2020 | First Faculty of Medicine
- Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study2023 | First Faculty of Medicine
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis2023 | First Faculty of Medicine, Central Library of Charles University
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaPublication without faculty affiliation
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study2018 | Second Faculty of Medicine
- Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial2019 | Publication without faculty affiliation
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial2020 | First Faculty of Medicine